Sex steroid hormones, bone mineral density, and risk of breast cancer

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 3, 1997, Pages 593-599

  Kuller, Lewis H ^a   Cauley, Jane A ^a   Lucas, Lee ^a   Cummings, Steve ^b   Browner, Warren S ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Breast cancer; Estrogen; Hormone replacement therapy

Indexed keywords

ESTROGEN; MARKER; SEX HORMONE;

ADULT; AGED; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER RISK; CONFERENCE PAPER; EXPOSURE; FEMALE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0030912550     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s3593     Document Type: Conference Paper

References (54)

1. Barrett-Connor E. Hormone replacement and cancer. Br Med Bull 48:345-355 (1992).
2. Cauley JA, Cummings SR, Dennis DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 163(5):1438-1444 (1990).
3. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67:327-332 (1996).
4. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037 (1992).
5. Kuller LH. The etiology of breast cancer - from epidemiology to prevention. Public Health Rev 23:157-213 (1995).
6. Colditz GA, Frazier AL. Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus. Cancer Epidemiol Biomarkers Prev 4:567-571 (1995).
7. Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, Tokunaga M. A case-control interview study of breast cancer among Japanese A-bomb survivors. II: Interactions with radiation dose. Cancer Causes Control 5:167-176 (1994).
8. Adlercreutz H. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 50(S201):3-23 (1990).
9. Bradlow HL, Hershcopf RJ, Fishman J. Oestradiol 16α-hydroxylase: a risk marker for breast cancer. Cancer Surv 5:573-583 (1986).
10. Rebbeck TR, Rosvold EA, Duggan DJ, Zhang J, Buetow KH. Genetics of CYP1A1: coamplification of specific alleles by polymerase chain reaction and association with breast cancer. Cancer Epidemiol Biomarkers Prev 3:511-514 (1994).
11. Trachman TE, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 55:3757-3758 (1995).
12. Leygue ER, Watson PH, Murphy LC. Estrogen receptor vanants in normal human mammary tissue. J Natl Cancer Inst 88:284-290 (1996).
13. Ford D, Easton F, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462 (1995).
14. Pike MC, Spicer DV, Dalmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17-35 (1993).
15. Jaffe RB. The menopause and perimenopausal period. Reproductive endocrinology: physiology, pathophysiology and clinical management. Philadelphia:W.B. Sanders, 1986.
16. Carr BR. Disorders of the Ovary and Female Reproductive Tract. In: Williams Textbook of Endocrinology. 8th ed. Philadelphia:W.B. Saunders, 1992;733-798.
17. Gow SM, Turner EI, Glasier A. The clinical biochemistry of the menopause and hormone replacement therapy. Ann Clin Biochem 31:509-528 (1994).
18. Brinton LA, Schairer C, Hoover RN, Fraumeni JF Jr. Menstrual factors and risk of breast cancer. Cancer Invest 6:245-254 (1988).
19. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. One hundred thirty-three randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85 (1992).
20. Nayfield SG, Karp JE, Ford LG, Dorr FP, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459 (1991).
21. Vermeulen A. Adrenal function in postmenopausal women. In: The menopause: clinical endocrinological and pathophysiological aspects (Fioretti P, Martini L, Melis GB, Yen SSC, eds). New York:Academic Press, 1992;133-138.
22. Judd H, Judd GE, Lucas WE, Yen SC. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39:1020 (1974).
23. Cauley JA, Gutai JP, Kuller LH, Powell JP. Reliability and interrelations among serum sex hormones in postmenopausal women. Am J Epidemiol 133:50-57 (1991).
24. Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P. Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. Arteriosclerosis 10:1058-1066 (1990).
25. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope L, Speizer FE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87:1297-1302 (1995).
26. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 154:2349-2355 (1994).
27. Cauley JA, Gutai JP, Kuller LH, Scott J, Mevitt MC. Black-white differences in serum sex hormones and bone mineral density. Am J Epidemiol 139:1035-1046 (1994).
28. Meilahn E, Herzog H, Sutton-Tyrrell K, Gutai J, Kuller L, Matthews K. Endogenous estrogen levels, lipoproteins and carotid artery wall thickness among postmenopausal women. Circulation 93:10 (1996).
29. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, Pasternack BS. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190-197 (1995).
30. Petrakis NL. Nipple aspirate fluid in epidemiologic studies of breast disease. Epidemiol Rev 15:188-195 (1993).
31. Santen RJ, Leszczynski, Tilson-Mallet N, Feil PO, Wright C, Manni A, Santner SJ. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways. Ann NY Acad Sci 464:126-137 (1986).
32. Azziz R. Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil Steril 52:703-725 (1989).
33. Morabia A, Wynder EL. Epidemiology and natural history of breast cancer: implications for the body weight-breast cancer controversy. Surg Clin North Am 70:739-752 (1990).
34. Schapira DV, Clard RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM. Visceral obesity and breast cancer risk. Cancer 74:632-639 (1994).
35. Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, Kahle L, Campbell WS, Tangrea JA, Schatzkin A. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 5:533-539 (1996).
36. Persson I, Adami HO, McLaughlin JK, Naessen T, Fraumeni JF. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 5:523-528 (1994).
37. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsburg TC, Riggs BL. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86 (1988).
38. Fox KM, Magaziner J, Sherwin R, Scott JC, Plato CC, Nevitt A, Cummings S. Reproductive correlates of bone mass in elderly women. J Bone Min Res 8:901-908 (1993).
39. Nilas L, Christiansen C. Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab 65:697-702 (1987).
40. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 95:375-395 (1993).
41. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and the risk of breast cancer in older women. The Study of Osteoporotic Fractures. JAMA 276:1404-1408 (1996).
42. Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P, Vogt TM and the Study of Osteoporotic Research Group. Appendicular bone density and age predict hip fracture in women. JAMA 263:665-668 (1990).
43. Miller BA, Ries LAG, Hankey BF, Kosary CL, Harras A, Devesa SS, Edwards BK, eds. SEER Cancer Statistics Review, 1973-1990, National Cancer Institute. NIH Publ No. 93-2789, 1993.
44. Cummings SR, Cauley JA, Lucas FL, Browner WS, Kuller LH. [Abstract] Women with vertebral fractures have a very low risk of breast cancer unless they take estrogen. The Study of Osteoporotic Fractures. ASBMR 18th Annual Meeting; J Bone Min Res 11:S139 (1996).
45. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85:6-10 (1995).
46. Jonas HA, Kronmal RA, Psaty BM, Manolio TA, Meilahn EH, Tell GS, Tracy RP, Robbins JA, Anton-Culver H for the Cardiovascular Health Study Collaborative Research Group. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. Ann Epidemiol 6:314-323 (1996).
47. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275:370-375 (1996).
48. Archer DF, Pickar JH, Bottiglioni F for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83:686-692 (1994).
49. Railo MJ, Smitten KV, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311 (1994).
50. Schmid C. IGF's: function and clinical importance. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. J Int Med 234:535-542 (1993).
51. Wing RR, Matthews KA, Kuller LH, Meilahn EN, Plantinga P. Weight gain at the time of the menopause. Arch Intern Med 151:97-102 (1991).
52. Rossouw JE, Finnegan CP, Harlow WR, Pinn VW, Clifford C, McGowan JA. The evolution of the Women's Health Initiative: Perspectives from the NIH. J Am Med Women's Assoc 50:50-55 (1994).
53. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Fourteenth Gaddum memorial lecture. Br J Pharmacol 110:507-517 (1993).
54. Spicer DV, Pike MC. Sex steroids and breast cancer prevention. Monogr Natl Cancer Inst 16:139-147 (1994).